Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

10x Genomics, Inc. - Common Stock (NQ:TXG)

60.10 +2.04 (+3.52%)
Delayed Quote Updated: 10:22 AM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 10x Genomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
What 10x Genomics (TXG) Said on Its Q3 Earnings Call ↗
10x Genomics (NASDAQ:TXG) raised its full-year revenue outlook after reporting modest third-quarter growth and increased its shipment target for its new Atera spatial biology platform. The company... 
Via MarketBeat
Topics Earnings Intellectual Property
News headline image
Meet the Unstoppable Vanguard ETF Beating the S&P 500 and the Dow Jones in 2026 ↗
Small-cap stocks have benefited from a range of tailwinds this year. 
Via The Motley Fool
Topics ETFs Economy Stocks
News headline image
10x Genomics (TXG) Q3 2026 Earnings Call Transcript ↗
Management flagged a margin step-down as Atera instrument shipments ramp in Q4. 
Via The Motley Fool
Topics Earnings
10X Genomics (NASDAQ:TXG) Earnings: EPS Beat, Revenue In Line, Shares Fall 10.4% ↗
Via Chartmill
News headline image
10x Genomics’s (NASDAQ:TXG) Q3 2026 sales top estimates but stock drops
Biotech company 10x Genomics (NASDAQ:TXG) reported Q3 2026 results topping the market’s revenue expectations, with revenue up 1.1% year on year to $150.7 mil... 
Via StockStory
Topics Artificial Intelligence
News headline image
10x Genomics (TXG) reports Q3: everything you need to know ahead of earnings
Biotech company 10x Genomics (NASDAQ:TXG) will be reporting results this Thursday after market close. Here’s what to look for. 10x Genomics beat analysts’ re... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 unprofitable stock with exciting potential and 2 that underwhelm
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th... 
Via StockStory
News headline image
3 Healthcare Stocks That Concern Us
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme... 
Via StockStory
News headline image
3 Reasons to Sell TXG and 1 Stock to Buy Instead
What a fantastic six months it’s been for 10x Genomics. Shares of the company have skyrocketed 187%, hitting $72.70. This was partly thanks to its solid quar... 
Via StockStory
Topics Supply Chain
News headline image
These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys? ↗
Forget the "Magnificent Seven" in favor of the "Tremendous Three"? 
Via The Motley Fool
News headline image
Why Are 10x Genomics (TXG) Shares Soaring Today
What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 6.1% in the morning session after Bank of America raised its price target on the st... 
Via StockStory
Topics Artificial Intelligence
News headline image
10x Genomics (TXG) Stock Is Up, What You Need To Know
What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 2.8% in the afternoon session after Argus analyst John Eade initiated coverage on t... 
Via StockStory
News headline image
Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid S... 
Via StockStory
News headline image
Q2 Rundown: 10x Genomics (NASDAQ:TXG) Vs Other Life Sciences Tools & Services Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Russell 2000 Stocks That Fall Short
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,... 
Via StockStory
News headline image
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know
What Happened? A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic conditions across broader equity ma... 
Via StockStory
News headline image
3 Inflated Stocks with Open Questions
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, u... 
Via StockStory
News headline image
3 Small-Cap Stocks with Open Questions
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
Via StockStory
News headline image
10x Genomics (TXG) Q2 2026 Earnings Call Transcript ↗
Atera demand drives spatial transition as booked orders exceed 2026 targets. 
Via The Motley Fool
Topics Earnings Intellectual Property World Trade
News headline image
5 Revealing Analyst Questions From 10x Genomics’s Q2 Earnings Call
10x Genomics’ second quarter results came in above Wall Street’s expectations for both revenue and profitability, yet the market responded negatively. Manage... 
Via StockStory
Topics Earnings
News headline image
1 High-Flying Stock to Own for Decades and 2 We Question
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo... 
Via StockStory
News headline image
10x Genomics Q2 Earnings Call Highlights ↗
10x Genomics (NASDAQ:TXG) reported second-quarter revenue of $151 million, including $1.6 million in license and royalty revenue tied to its settlement with Takara. Excluding non-recurring settlement... 
Via MarketBeat
Topics Earnings
News headline image
TXG Q2 Deep Dive: Atera Launch Signals Transition as Spatial Market Shifts
Biotech company 10x Genomics (NASDAQ:TXG) reported Q2 CY2026 results exceeding the market’s revenue expectations, but sales fell by 12.6% year on year to $15... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Unpopular Stock That Deserves Some Love and 2 That Underwhelm
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord... 
Via StockStory
News headline image
10x Genomics’s (NASDAQ:TXG) Q2 CY2026: Strong Sales, Full-Year Outlook Slightly Exceeds Expectations
Biotech company 10x Genomics (NASDAQ:TXG) reported Q2 CY2026 results topping the market’s revenue expectations, but sales fell by 12.6% year on year to $151 ... 
Via StockStory
News headline image
10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect
Biotech company 10x Genomics (NASDAQ:TXG) will be announcing earnings results this Thursday after market close. Here’s what to expect. 10x Genomics beat anal... 
Via StockStory
News headline image
1 Surging Stock with Solid Fundamentals and 2 Facing Headwinds
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos... 
Via StockStory
News headline image
1 Healthcare Stock to Keep an Eye On and 2 We Avoid
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali... 
Via StockStory
News headline image
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HC... 
Via StockStory
News headline image
1 Cash-Producing Stock with Exciting Potential and 2 Facing Challenges
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.